EMERGENT BIOSOLUTIONS INC. Intangible Assets, Net (Excluding Goodwill)
EMERGENT BIOSOLUTIONS INC. (EBS) had Intangible Assets, Net (Excluding Goodwill) of $261.80 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-06
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $261.80M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $470.40M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $436.50M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $452.70M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $261.80M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $470.40M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $436.50M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $452.70M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $469.00M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $485.20M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $501.50M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $517.80M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $534.10M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $550.40M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $566.60M 10-K · filed 2025-03-04 | |
| 2023-09-30 | $582.80M 10-Q · filed 2023-12-11 | |
| 2023-06-30 | $592.80M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $608.90M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $728.80M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $724.90M 10-Q · filed 2023-12-11 | $722.70M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $576.60M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $590.60M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $604.60M 10-K/A · filed 2023-12-11 | |
| 2021-09-30 | $618.60M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $633.10M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $648.20M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $663.10M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $678.10M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $693.20M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $708.10M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $712.90M 10-K · filed 2021-02-19 | |
| 2019-09-30 | $727.70M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $742.40M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $757.10M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $761.60M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $107.86M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $111.77M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $115.69M 10-Q · filed 2018-05-04 | |
| 2017-12-31 | $119.60M 10-K · filed 2019-02-22 | $119.60M 10-K · filed 2018-02-23 |
| 2017-09-30 | $29.20M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $30.76M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $32.31M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $33.87M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $35.42M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $52.65M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $55.01M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $40.76M 10-K · filed 2017-02-28 | $57.38M 10-K · filed 2016-02-29 |
| 2015-09-30 | $59.74M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $62.11M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $56.20M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $58.34M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $64.46M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $66.68M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $68.93M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $30.15M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |